debest (Q5978225): Difference between revisions
From MaRDI portal
Changed an Item |
Added link to MaRDI item. |
||
| (One intermediate revision by one other user not shown) | |||
| Property / MaRDI profile type | |||
| Property / MaRDI profile type: MaRDI software profile / rank | |||
Normal rank | |||
| links / mardi / name | links / mardi / name | ||
Latest revision as of 19:10, 12 March 2024
Duration Estimation for Biomarker Enrichment Studies and Trials
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | debest |
Duration Estimation for Biomarker Enrichment Studies and Trials |
Statements
A general framework using mixture Weibull distributions to accurately predict biomarker-guided trial duration accounting for heterogeneous population. Extensive simulations are performed to evaluate the impact of heterogeneous population and the dynamics of biomarker characteristics and disease on the study duration. Several influential parameters including median survival time, enrollment rate, biomarker prevalence and effect size are identified. Efficiency gains of biomarker-guided trials can be quantitatively compared to the traditional all-comers design. For reference, see Zhang et al. (2024) <arXiv:2401.00540>.
0 references
10 January 2024
0 references
